StocksMedium•24 September 2026•
1 min read
Prime Medicine Receives FDA Clearance for PM647 Clinical Trials
Key Facts
1Prime Medicine received U.S. FDA clearance for its Investigational New Drug (IND) application for PM647.
2The drug targets Alpha-1 Antitrypsin Deficiency, with initial clinical data expected in 2027.
Prime Medicine received U.S. FDA clearance for its Investigational New Drug (IND) application for PM647. The drug targets Alpha-1 Antitrypsin Deficiency, and the company stated in a GlobeNewswire release that the clearance allows it to proceed with clinical trials. Initial clinical data from the study is expected to be available in 2027.
PRME closed at $3.13 on September 23, 2026, prior to the announcement of this regulatory milestone aimed at expanding the company's liver franchise. This development follows previous regulatory clearances for other candidates such as PM577a, supporting the company's broader clinical strategy.